ɬÀï·¬

News

Breaking down fat byproducts could lead to healthier aging

Eyleen Jorgelina O’Rourke
By Eyleen Jorgelina O’Rourke
March 17, 2024

The journey of aging brings with it an unavoidable reality for many: an increased accumulation of body fat. Though much of society seems mostly focused on the aesthetics of being overweight, doctors look past any cosmetic concerns to focus on the health implications of fat byproducts in the body.

are one of the molecular building blocks that make up fats. Though essential for various bodily functions, excessive amounts of fatty acids in the body , shortening a person’s by increasing their risk of chronic disease, disrupting metabolic processes and promoting inflammation.

Fatty acids are during medical examinations, such as blood tests measuring your lipid profile. But clinicians and researchers often overlook the other key component of fat despite its potentially harmful effects: , a compound that links fatty acids to make a fat molecule.

Both of these fat byproducts disrupt cellular and organ function, mirroring the effects of aging. In fact, researchers are increasingly seeing obesity as a .

The role that fats play in aging is one of the focuses of my work as a . My and I wondered whether reducing harmful fat byproducts might help slow the aging process and consequently stave off common diseases.

Fats perform essential functions in your cells, but not all of them are good for you.

Breaking down fat byproducts

In studying ways to extend the life span and improving the health at late age of lab animals, my colleagues and I saw a : All the anti-aging interventions we tested led to reduced glycerol levels.

For instance, when placed on a calorie-restricted diet, the nematode Caenorhabditis elegans . We found that the glycerol levels in the body of these long-lived worms were lower than in shorter-lived worms that were not food restricted. Calorie restriction also responsible for breaking down glycerol, ADH-1, in their intestine and muscles.

We saw similar undergoing dietary restriction or treated with an anti-aging drug called rapamycin. This finding suggests there may be a common mechanism underlying healthy aging across species, with ADH-1 at its core.

,
Triacylglycerols, also known as triglycerides, are composed of a glycerol linked to three fatty acids.

We hypothesized that elevated ADH-1 activity promotes health in old age by decreasing harmful levels of glycerol. Supporting this hypothesis were . First, we found that adding glycerol to the diet of worms . By contrast, animals genetically modified to boost levels of the glycerol-busting enzyme ADH-1 had low glycerol levels and remained lean and healthy with longer lives, even on unrestricted diets.

The simple molecular structure and wealth of research on ADH-1 make it an attractive target for developing drugs that boost its activity. My lab’s long-term goal is to explore how compounds that activate ADH-1 affect the health and longevity of both mice and people.

A long-lived society

Anti-aging research generates both excitement and debate. On the one hand, the benefits of are clear. On the other hand, extending life span through healthier aging will likely introduce new societal challenges.

If life spans extending to 120 years become the norm, , including retirement ages and economic models, will need to evolve to accommodate an aging population. Legal and social frameworks regarding the elderly and family care may need revision. The , those with children and living parents and grandparents, might find themselves caring for even more generations simultaneously. Longer lives will require society to rethink and reshape how we integrate and support an increasingly older population in our communities.

Whether through ADH-1 or dietary adjustments, the quest for the solution to healthy aging is not just a medical journey but a societal one.The Conversation

This article is republished from under a Creative Commons license. Read the .

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Eyleen Jorgelina O’Rourke
Eyleen Jorgelina O’Rourke

Eyleen Jorgelina O’Rourke is an associate professor of biology and cell biology at the University of Virginia.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

What’s in a diagnosis?
Essay

What’s in a diagnosis?

Sept. 4, 2025

When Jessica Foglio’s son Ben was first diagnosed with cerebral palsy, the label didn’t feel right. Whole exome sequencing revealed a rare disorder called Salla disease. Now Jessica is building community and driving research for answers.

Peer through a window to the future of science
Annual Meeting

Peer through a window to the future of science

Sept. 3, 2025

Aaron Hoskins of the University of Wisconsin–Madison and Sandra Gabelli of Merck, co-chairs of the 2026 ASBMB annual meeting, to be held March 7–10, explain how this gathering will inspire new ideas and drive progress in molecular life sciences.

Glow-based assay sheds light on disease-causing mutations
Journal News

Glow-based assay sheds light on disease-causing mutations

Sept. 2, 2025

University of Michigan researchers create a way to screen protein structure changes caused by mutations that may lead to new rare disease therapeutics.

How signals shape DNA via gene regulation
Journal News

How signals shape DNA via gene regulation

Aug. 19, 2025

A new chromatin isolation technique reveals how signaling pathways reshape DNA-bound proteins, offering insight into potential targets for precision therapies. Read more about this recent ɬÀï·¬ paper.

A game changer in cancer kinase target profiling
Journal News

A game changer in cancer kinase target profiling

Aug. 19, 2025

A new phosphonate-tagging method improves kinase inhibitor profiling, revealing off-target effects and paving the way for safer, more precise cancer therapies tailored to individual patients. Read more about this recent ɬÀï·¬ paper.

How scientists identified a new neuromuscular disease
Feature

How scientists identified a new neuromuscular disease

Aug. 14, 2025

NIH researchers discover Morimoto–Ryu–Malicdan syndrome, after finding shared symptoms and RFC4 gene variants in nine patients, offering hope for faster diagnosis and future treatments.